GB201514875D0 - Receptor - Google Patents

Receptor

Info

Publication number
GB201514875D0
GB201514875D0 GBGB1514875.2A GB201514875A GB201514875D0 GB 201514875 D0 GB201514875 D0 GB 201514875D0 GB 201514875 A GB201514875 A GB 201514875A GB 201514875 D0 GB201514875 D0 GB 201514875D0
Authority
GB
United Kingdom
Prior art keywords
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1514875.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Priority to GBGB1514875.2A priority Critical patent/GB201514875D0/en
Publication of GB201514875D0 publication Critical patent/GB201514875D0/en
Priority to HK18111554.5A priority patent/HK1252161A1/zh
Priority to JP2018509549A priority patent/JP2018523485A/ja
Priority to RU2018109350A priority patent/RU2018109350A/ru
Priority to EP18189793.5A priority patent/EP3438123A1/en
Priority to AU2016308618A priority patent/AU2016308618B2/en
Priority to EP23216609.0A priority patent/EP4338756A3/en
Priority to CA3091907A priority patent/CA3091907C/en
Priority to KR1020247017118A priority patent/KR20240093884A/ko
Priority to US15/753,486 priority patent/US10800854B2/en
Priority to CA2995785A priority patent/CA2995785A1/en
Priority to NZ739942A priority patent/NZ739942B2/en
Priority to CN201911010436.8A priority patent/CN110724200B/zh
Priority to PCT/GB2016/052564 priority patent/WO2017029512A1/en
Priority to CN201680046834.3A priority patent/CN108350047A/zh
Priority to SG10201909759U priority patent/SG10201909759UA/en
Priority to MX2018002042A priority patent/MX2018002042A/es
Priority to IL270207A priority patent/IL270207B2/en
Priority to KR1020187007751A priority patent/KR102669749B1/ko
Priority to EP16756758.5A priority patent/EP3337814A1/en
Priority to BR112018003308-1A priority patent/BR112018003308A2/pt
Priority to IL257234A priority patent/IL257234A/en
Priority to CL2018000415A priority patent/CL2018000415A1/es
Priority to MX2019013204A priority patent/MX2019013204A/es
Priority to US16/113,224 priority patent/US10800855B2/en
Priority to CL2019001107A priority patent/CL2019001107A1/es
Priority to JP2019113625A priority patent/JP6979423B2/ja
Priority to ZA2019/04156A priority patent/ZA201904156B/en
Priority to US16/998,756 priority patent/US11479613B2/en
Priority to US16/999,012 priority patent/US11479614B2/en
Priority to JP2020199336A priority patent/JP7603426B2/ja
Priority to US17/815,110 priority patent/US12234295B2/en
Priority to JP2022178045A priority patent/JP2022190153A/ja
Priority to US19/033,252 priority patent/US20250333538A1/en
Priority to JP2025047075A priority patent/JP2025089404A/ja
Priority to JP2025047074A priority patent/JP2025089403A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
GBGB1514875.2A 2015-08-20 2015-08-20 Receptor Ceased GB201514875D0 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
GBGB1514875.2A GB201514875D0 (en) 2015-08-20 2015-08-20 Receptor
EP16756758.5A EP3337814A1 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
MX2018002042A MX2018002042A (es) 2015-08-20 2016-08-19 Receptor.
JP2018509549A JP2018523485A (ja) 2015-08-20 2016-08-19 キメラサイトカイン受容体
RU2018109350A RU2018109350A (ru) 2015-08-20 2016-08-19 Химерный цитокиновый рецептор
EP18189793.5A EP3438123A1 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
AU2016308618A AU2016308618B2 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
EP23216609.0A EP4338756A3 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
CA3091907A CA3091907C (en) 2015-08-20 2016-08-19 Cell comprising a chimeric antigen receptor (car) and a constitutively active cytokine-signalling chimeric transmembrane protein
KR1020247017118A KR20240093884A (ko) 2015-08-20 2016-08-19 키메라 사이토카인 수용체
US15/753,486 US10800854B2 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptors and encoding nucleic acids
CA2995785A CA2995785A1 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
NZ739942A NZ739942B2 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
CN201911010436.8A CN110724200B (zh) 2015-08-20 2016-08-19 嵌合细胞因子受体
PCT/GB2016/052564 WO2017029512A1 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
CN201680046834.3A CN108350047A (zh) 2015-08-20 2016-08-19 嵌合细胞因子受体
SG10201909759U SG10201909759UA (en) 2015-08-20 2016-08-19 Chimeric Cytokine Receptor
HK18111554.5A HK1252161A1 (zh) 2015-08-20 2016-08-19 嵌合细胞因子受体
KR1020187007751A KR102669749B1 (ko) 2015-08-20 2016-08-19 키메라 사이토카인 수용체
IL270207A IL270207B2 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor
BR112018003308-1A BR112018003308A2 (pt) 2015-08-20 2016-08-19 receptor quimérico de citocina
IL257234A IL257234A (en) 2015-08-20 2018-01-30 Chimeric cytokine receptor
CL2018000415A CL2018000415A1 (es) 2015-08-20 2018-02-15 Receptor quimerica de citocinas.
MX2019013204A MX2019013204A (es) 2015-08-20 2018-02-16 Receptor.
US16/113,224 US10800855B2 (en) 2015-08-20 2018-08-27 Chimeric cytokine receptors and encoding nucleic acids
CL2019001107A CL2019001107A1 (es) 2015-08-20 2019-04-23 Receptor quimérico de citocinas. (divisional solicitud 201800415).
JP2019113625A JP6979423B2 (ja) 2015-08-20 2019-06-19 キメラサイトカイン受容体
ZA2019/04156A ZA201904156B (en) 2015-08-20 2019-06-26 Chimeric cytokine receptor
US16/998,756 US11479613B2 (en) 2015-08-20 2020-08-20 Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins
US16/999,012 US11479614B2 (en) 2015-08-20 2020-08-20 Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors
JP2020199336A JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体
US17/815,110 US12234295B2 (en) 2015-08-20 2022-07-26 Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
JP2022178045A JP2022190153A (ja) 2015-08-20 2022-11-07 キメラサイトカイン受容体
US19/033,252 US20250333538A1 (en) 2015-08-20 2025-01-21 Chimeric cytokine receptor
JP2025047075A JP2025089404A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体
JP2025047074A JP2025089403A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1514875.2A GB201514875D0 (en) 2015-08-20 2015-08-20 Receptor

Publications (1)

Publication Number Publication Date
GB201514875D0 true GB201514875D0 (en) 2015-10-07

Family

ID=54292003

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1514875.2A Ceased GB201514875D0 (en) 2015-08-20 2015-08-20 Receptor

Country Status (17)

Country Link
US (6) US10800854B2 (enExample)
EP (3) EP3438123A1 (enExample)
JP (6) JP2018523485A (enExample)
KR (2) KR20240093884A (enExample)
CN (2) CN108350047A (enExample)
AU (1) AU2016308618B2 (enExample)
BR (1) BR112018003308A2 (enExample)
CA (2) CA3091907C (enExample)
CL (2) CL2018000415A1 (enExample)
GB (1) GB201514875D0 (enExample)
HK (1) HK1252161A1 (enExample)
IL (2) IL270207B2 (enExample)
MX (2) MX2018002042A (enExample)
RU (1) RU2018109350A (enExample)
SG (1) SG10201909759UA (enExample)
WO (1) WO2017029512A1 (enExample)
ZA (1) ZA201904156B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
EP3541833B1 (en) * 2016-11-17 2024-01-24 2seventy bio, Inc. Tgf beta signal convertor
JP7206214B2 (ja) 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3679145A2 (en) * 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
GB201714718D0 (en) * 2017-09-13 2017-10-25 Autolus Ltd Cell
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
GB201719557D0 (en) * 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
EP3723787A4 (en) * 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
WO2019169290A1 (en) * 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
BR112020020887A2 (pt) 2018-04-12 2021-04-06 Umoja Biopharma, Inc Vetores virais e linhagens celulares de empacotamento
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
CA3103936A1 (en) * 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
JP7560882B2 (ja) * 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
EP3856775B9 (en) 2018-09-27 2025-01-22 Autolus Limited Chimeric antigen receptor
US20200147137A1 (en) * 2018-11-08 2020-05-14 WUGEN, Inc. Compositions and methods for treatment of cancer
CN111378046B (zh) * 2018-12-27 2024-03-15 上海细胞治疗集团有限公司 一种免疫效应细胞转换受体
US11786553B2 (en) 2019-03-01 2023-10-17 Allogene Therapeuctics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
PH12021551861A1 (en) 2019-03-01 2022-05-30 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
JP2022548069A (ja) * 2019-09-11 2022-11-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラ直交受容体タンパク質および使用方法
KR102275668B1 (ko) * 2019-09-26 2021-07-12 충북대학교 산학협력단 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
US20240058302A1 (en) * 2019-10-10 2024-02-22 Bryologyx Inc. Method of induction of tumor associated antigens with bryostatin
AU2021227191A1 (en) 2020-02-24 2022-08-25 Allogene Therapeutics, Inc. BCMA car-T cells with enhanced activities
EP4110801A1 (en) * 2020-02-25 2023-01-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
WO2021202793A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Chimeric antigen receptors targeting cd33
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
CN113201063B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途
WO2022037562A1 (en) * 2020-08-17 2022-02-24 Nanjing Legend Biotech Co., Ltd. Engineered immunoresponsive cells and uses thereof
CN112961248B (zh) * 2021-02-22 2022-03-18 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用
CN113072648B (zh) * 2021-06-04 2021-08-24 诺未科技（北京）有限公司 一种靶向afp的肝癌疫苗
CN113416708A (zh) * 2021-06-10 2021-09-21 深圳市先康达生命科学有限公司 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用
US20230086030A1 (en) * 2021-08-30 2023-03-23 Industry-Academic Cooperation Foundation, Yonsei University Lymphoma cell-specific drug delivery system for prevention or treatment of lymphoma and method for preparing same
CA3232668A1 (en) 2021-09-17 2023-03-23 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
EP4519294A1 (en) * 2022-05-04 2025-03-12 Earli Inc. Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells
AU2023306306A1 (en) * 2022-07-11 2025-01-02 Sonoma Biotherapeutics, Inc. Recombinant cytokine receptors and methods of use
WO2024044768A2 (en) * 2022-08-26 2024-02-29 The Board Of Trustees Of The Leland Stanford Junior University Chimeric cytokine receptors and methods of use
CN117402262A (zh) * 2022-10-19 2024-01-16 上海君赛生物科技有限公司 基于lag3的嵌合免疫细胞辅助受体及其用途
WO2024123835A1 (en) * 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
AU2024212695A1 (en) 2023-01-23 2025-08-14 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
KR20250165594A (ko) 2023-02-07 2025-11-26 퀠 테라퓨틱스 리미티드 Treg 세포의 배양 방법
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
AU2024240076A1 (en) 2023-03-20 2025-08-28 Autolus Limited A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma
WO2024238287A1 (en) * 2023-05-12 2024-11-21 Chimeris Uk Ltd. Dual blocking and chimeric cytokine receptor
GB202309704D0 (en) 2023-06-27 2023-08-09 Autolus Ltd Chimeric transmembrane protein
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
WO2025189046A2 (en) * 2024-03-06 2025-09-12 The Johns Hopkins University Pantigen specific cytokine receptor stimulation of immune cell function
WO2025221843A1 (en) * 2024-04-17 2025-10-23 Baylor College Of Medicine Methods and compositions for suppressing immune cell activation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683073B2 (en) 1993-06-07 1997-10-30 Amgen, Inc. Hybrid receptor molecules
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
DK1066380T3 (da) * 1998-05-19 2002-01-28 Avidex Ltd Opløselig T-cellereceptor
AU2002245652A1 (en) * 2001-03-09 2002-09-24 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
BR0309401A (pt) * 2002-04-19 2007-02-21 Zymogenetics Inc polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
JP2004113062A (ja) 2002-09-25 2004-04-15 Teruyuki Nagamune キメラ受容体を有する動物細胞とその利用
CN101027079B (zh) * 2004-10-12 2011-08-17 美国蛋白质公司 嵌合蛋白
WO2007115230A2 (en) * 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
WO2008045437A2 (en) * 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
US9206440B2 (en) 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
NZ723731A (en) 2011-04-08 2020-05-29 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
RU2522004C2 (ru) 2012-04-10 2014-07-10 Владимир Константинович Боженко Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения.
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
EP3856775B9 (en) 2018-09-27 2025-01-22 Autolus Limited Chimeric antigen receptor

Also Published As

Publication number Publication date
CA3091907C (en) 2023-10-31
EP3438123A1 (en) 2019-02-06
KR20240093884A (ko) 2024-06-24
CN110724200B (zh) 2024-01-26
RU2018109350A (ru) 2019-09-23
US12234295B2 (en) 2025-02-25
EP4338756A3 (en) 2024-06-05
JP2018523485A (ja) 2018-08-23
IL270207B2 (en) 2024-06-01
BR112018003308A2 (pt) 2018-09-18
JP2019150066A (ja) 2019-09-12
JP2021035395A (ja) 2021-03-04
MX2018002042A (es) 2018-06-19
CN108350047A (zh) 2018-07-31
US20210040228A1 (en) 2021-02-11
RU2018109350A3 (enExample) 2019-12-09
US20210040227A1 (en) 2021-02-11
EP3337814A1 (en) 2018-06-27
US20230133682A1 (en) 2023-05-04
JP2025089404A (ja) 2025-06-12
CA3091907A1 (en) 2017-02-23
SG10201909759UA (en) 2019-11-28
CN110724200A (zh) 2020-01-24
IL257234A (en) 2018-03-29
IL270207B1 (en) 2024-02-01
US20250333538A1 (en) 2025-10-30
US20190016820A1 (en) 2019-01-17
KR20180054625A (ko) 2018-05-24
JP7603426B2 (ja) 2024-12-20
MX2019013204A (es) 2020-01-21
EP4338756A2 (en) 2024-03-20
CA2995785A1 (en) 2017-02-23
US10800854B2 (en) 2020-10-13
NZ739942A (en) 2022-03-25
AU2016308618A1 (en) 2018-03-08
US10800855B2 (en) 2020-10-13
CL2019001107A1 (es) 2019-07-05
AU2016308618B2 (en) 2021-05-13
US11479614B2 (en) 2022-10-25
JP2022190153A (ja) 2022-12-22
IL270207A (enExample) 2019-12-31
CL2018000415A1 (es) 2018-07-20
WO2017029512A1 (en) 2017-02-23
ZA201904156B (en) 2025-09-25
HK1252161A1 (zh) 2019-05-17
JP2025089403A (ja) 2025-06-12
US11479613B2 (en) 2022-10-25
JP6979423B2 (ja) 2021-12-15
US20180244797A1 (en) 2018-08-30
KR102669749B1 (ko) 2024-05-28

Similar Documents

Publication Publication Date Title
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
DK3389557T3 (en) Transseptalt leveringssystem
DK3320033T3 (en) Polyethylenterephthalat-depolymerisering
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
DK3250592T3 (en) Anti-transthyretin-antistoffer
DK3298030T3 (en) Anti-cancerfusionspolypeptid
GB201500806D0 (en) Aerosol-gnerating aticle
DK3373882T3 (en) Patientisolator
DK3284069T3 (en) Pos-terminal
DK3390996T3 (en) Trykbart tids-temperaturindikatorsystem
DK3380145T3 (en) Injektionsapparat
DK3336185T3 (en) Antistof
GB201702617D0 (en) Receptor
DK3272750T3 (en) Morphinan-derivat
DK3324768T3 (en) Tørdragt
PL3245344T3 (pl) Konstrukcja słupowo-ryglowa
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3242882T3 (en) Cgrp-antagonistpeptider
DK3282866T3 (en) Proteinfibre
DK3294653T3 (en) Justerbar inline-port
GB2535510B (en) Fixing means
GB201701887D0 (en) Receptor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)